Skip to main content
SpringerLink
Log in

Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases

  • Review
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

The availability of agents that block the biological activity of tumor necrosis factor α (TNFα) in rheumatoid arthritis (RA) has permitted studies that confirm the key role of this cytokine in the pathogenesis of this disease. To date, two anti-TNF agents, infliximab and etanercept, have been approved for use in treatment. Clinical trials of these agents demonstrate efficacy for the control of symptoms and signs and acceptable safety in patients who have failed to respond adequately to conventional therapy. Combination with methotrexate appears to be particularly effective and may provide the main initial indication for clinical application in the first instance. Repeated administration of anti-TNF therapies over a one year period results in sustained reduction in symptoms and signs of RA in the majority of patients. It has recently become apparent that anti-TNF therapy protects joints from structural damage. These findings imply that TNFα has a critical role in the bone and cartilage damage associated with RA.

Evidence to date support the hypothesis that there are 2 particularly important mechanisms of action; deactivation of the proinflammatory cytokine cascade at the site of inflammation and diminished recruitment of inflammatory cells from blood to the rheumatoid joint.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105–1110.

    Article  PubMed  CAS  Google Scholar 

  2. Pincus, T. and Callahan, L. F. (1993) What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am. 19, 123–151.

    PubMed  CAS  Google Scholar 

  3. Sharp, J. T., Wolfe, F., Mitchell, D. M., and Bloch, D. A. (1991) The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum. 34, 660–668.

    Article  PubMed  CAS  Google Scholar 

  4. Janossy, G., Panayi, G., Duke, O., Bofill, M., Poulter, L. W., and Goldstein, G. (1981) Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet ii, 839–841.

    Article  Google Scholar 

  5. Cush, J. J. and Lipsky, P. E. (1988) Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum. 31, 1230–1238.

    Article  PubMed  CAS  Google Scholar 

  6. Firestein, G. S. and Zvaifler, N. J. (1990) How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33, 768–773.

    Article  PubMed  CAS  Google Scholar 

  7. Miossec, P., Naviliat, M., D’Angeac, A. D., Sany, J., and Banchereau, J. (1990) Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis Rheum. 33, 1180–1187.

    Article  PubMed  CAS  Google Scholar 

  8. Feldmann, M., Brennan, F. M., and Maini, R. N. (1996) Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14, 397–440.

    Article  CAS  Google Scholar 

  9. Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N., and Feldmann, M. (1988) Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin. Exp. Immunol. 73, 449–455.

    PubMed  CAS  Google Scholar 

  10. Brennan, F. M., Chantry, D., Jackson, A., Maini, R., and Feldmann, M. (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244–247.

    Article  PubMed  CAS  Google Scholar 

  11. Butler, D., Maini, R. N., Feldmann, M., and Brennan, F. M. (1995) Blockade of TNFα with chimeric anti TNFα monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA NMC cultures: A comparison with IL-1ra. submitted. Eur. Cytokine. Netw. 6, 225–230.

    PubMed  CAS  Google Scholar 

  12. Dayer, J. M., Beutler, B., and Cerami, A. (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162, 2163–2168.

    Article  PubMed  CAS  Google Scholar 

  13. Katsikis, P. D., Chu, C. Q., Brennan, F. M., Maini, R. N., and Feldmann, M. (1994) Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J. Exp. Med. 179, 1517–1527.

    Article  PubMed  CAS  Google Scholar 

  14. Fava, R., Olsen, N., Keski-Oja, J., Moses, H., and Pincus, T. (1989) Active and latent forms of transforming growth factor β activity in synovial effusions. J. Exp. Med. 169, 291–296.

    Article  PubMed  CAS  Google Scholar 

  15. Wahl, S. M. (1994) Transforming growth factor β: The Good, the Bad, and the Ugly. J. Exp. Med. 180, 1587–1590.

    Article  PubMed  CAS  Google Scholar 

  16. Cope, A. P., Aderka, D., Doherty, M., et al. (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatoid diseases. Arthritis Rheum. 35, 1160–1169.

    Article  PubMed  CAS  Google Scholar 

  17. Coley, W. (1893) The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487–511.

    Article  Google Scholar 

  18. Aggarwal, B. B., Kohr, W. J., Hass, P. E., et al. (1985) Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 260, 2345–2354.

    PubMed  CAS  Google Scholar 

  19. Pennica, D., Nedwin, G. E., Hayflick, J. S., Hayflick, P. H. S., et al. (1984) Human tumor necrosis factor: precursor structure expression and homology to lymphotoxin. Nature 312, 724–729.

    Article  PubMed  CAS  Google Scholar 

  20. Shirai, T., Yamaguchi, H., Ito, H., Todd, C. W., and Wallace, R. B. (1985) Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature 313, 803–809.

    Article  PubMed  CAS  Google Scholar 

  21. Wang, A. M., Creasey, A. A., Ladner, M. B., et al. (1985) Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228, 149–154.

    Article  PubMed  CAS  Google Scholar 

  22. Beutler, B. and Cerami, A. (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin [review]. Nature 320, 584–588.

    Article  PubMed  CAS  Google Scholar 

  23. Jones, E. Y., Stuart, D. I., and Walker, N. P. C. (1989) Structure of tumor necrosis factor. Nature 338, 225–228.

    Article  PubMed  CAS  Google Scholar 

  24. Bazzoni, F. and Beutler, B. (1996) The tumor necrosis factor ligand and receptor families (review). N. Engl. J. Med. 334, 1717–1725.

    Article  PubMed  CAS  Google Scholar 

  25. Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D., and Wallach, D. (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264, 11,974–11,980.

    CAS  Google Scholar 

  26. Seckinger, P., Isaaz, S., and Dayer, J. M. (1988) A human inhibitor of tumor necrosis factor α. J. Exp. Med. 167, 1511–1516.

    Article  PubMed  CAS  Google Scholar 

  27. Poltorak, A., Peppel, K., and Beutler, B. (1994) Receptor-mediated label-transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. J. Immunol. Methods 169, 93–99.

    Article  PubMed  CAS  Google Scholar 

  28. Tracey, K. J. and Cerami, A. (1994) Tumor necrosis factor: a pleiotropic cytokine and therapeutic target (review). Ann. Rev. Med. 45, 491–503.

    Article  PubMed  CAS  Google Scholar 

  29. Negussie, Y., Remick, D. G., DeForge, L. E., Kunkel, S. L., Eynon, A., and Griffin, G. E. (1992) Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer reaction of relapsing fever. J. Exp. Med. 175, 1207–1212.

    Article  PubMed  CAS  Google Scholar 

  30. Chatenoud, L., Ferran, C., Reuter, A., et al. (1989) Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N. Engl. J. Med. 320, 1420,1421.

    Article  PubMed  CAS  Google Scholar 

  31. Dayer, J. M. and Burger, D. (1994) Interleukin-1, tumor necrosis facto and their specific inhibitors [review]. Eur. Cytokine Netw. 5, 563–571.

    PubMed  CAS  Google Scholar 

  32. Marchant, A., Bruyns, C., Vanderabeele, P., et al. (1994) Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 24, 1167–1171.

    Article  PubMed  CAS  Google Scholar 

  33. Espevik, T., Figari, I. S., Shalaby, M. R., et al. (1987) Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J. Exp. Med. 166, 571–576.

    Article  PubMed  CAS  Google Scholar 

  34. Han, J., Thompson, P., and Beutler, B. (1990) Dexamethasone and pentoxifylline inhibit endotoxin induced TNF synthesis at separate points in their signaling pathway. J. Exp. Med. 172, 391–394.

    Article  PubMed  CAS  Google Scholar 

  35. Parmely, M. J., Zhou, W. W., Edwards, C. K., Borcherding, D. R., Silverstein, R., and Morrison, D. C. (1993) Adenosine and a related cabocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J. Immunol. 151, 389–396.

    PubMed  CAS  Google Scholar 

  36. Bouma, M. G., Stad, R. K., van den Wildenberg, F. A., and Buurman, W. A. (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J. Immunol. 153, 4159–4168.

    PubMed  CAS  Google Scholar 

  37. Vannier, E., Miller, L. C., and Dinarello, C. A. (1991) Histamine suppressess gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors. J. Exp. Med. 174, 281–284.

    Article  PubMed  CAS  Google Scholar 

  38. Florquin, S., Amraoui, Z., Dubois, C., Decuyper, J., and Goldman, M. (1994) The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J. Exp. Med. 180, 1153–1158.

    Article  PubMed  CAS  Google Scholar 

  39. Eigler, A., Moeller, J., and Endres, S. (1995) Exogenous and endogenous nitric oxide attenuate tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. J. Immunol. 154, 4048–4054.

    PubMed  CAS  Google Scholar 

  40. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675–1680.

    Article  PubMed  CAS  Google Scholar 

  41. Keffer, J., Probert, L., Cazlaris, H., et al. (1991) Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025–4031.

    PubMed  CAS  Google Scholar 

  42. Williams, R. O., Feldmann, M., and Maini, R. N. (1992) Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784–9788.

    Article  PubMed  CAS  Google Scholar 

  43. Knight, D. M., Trinh, H., Le, J., et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443–1453.

    Article  PubMed  CAS  Google Scholar 

  44. Winter, G. and Harris, W. J. (1993) Humanized antibodies. Immunol. Today 14, 243–246.

    Article  PubMed  CAS  Google Scholar 

  45. Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36, 1681–1690.

    Article  PubMed  CAS  Google Scholar 

  46. Paulus, H. E., Egger, M. J., Ward, J. R., and Williams, H. J. (1990) The Cooperative Systemic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum. 33, 477–484.

    Article  PubMed  CAS  Google Scholar 

  47. Feldmann, M., Elliott, M. J., Woody, J. N., and Maini, R. N. (1997) Anti-tumor necrosis factor-a therapy in rheumatoid arthritis. Adv. Immunol. 64, 283–350.

    Article  PubMed  CAS  Google Scholar 

  48. Davis, D., Charles, P. J., Potter, A., Feldmann, M., Maini, R. N., and Elliott, M. J. (1997) Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumor necrosis factor α. Br. J. Rheum. 36, 950–956.

    Article  CAS  Google Scholar 

  49. Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Repeated therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1128.

    Article  PubMed  CAS  Google Scholar 

  50. Maini, R. N., Elliott, M. J., Brennan, F. M., et al. (1995) Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144, 195–223.

    Article  PubMed  CAS  Google Scholar 

  51. Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis (RA). Arthritis Rheum. 41, 1552–1563

    Article  PubMed  CAS  Google Scholar 

  52. Maini, R. N., St. Clair, E. William, Breedveld, F., et al. (1999) For the ATTRACT Study Group Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients rerceiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932–1939.

    Article  PubMed  CAS  Google Scholar 

  53. Lipsky, P. E., van der Heidje, D. M. F. M., St. Clair, E. William, et al. (2000) For the ATTRACT Study Group Infliximab and methotrexate in the treatment of Rheumatoid Arthritis. N. Engl. J. Med. 343, 1594–1602.

    Article  PubMed  CAS  Google Scholar 

  54. Rankin, E. C. C., Choy, E. H. S., Kassimos, D., et al. (1995) The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34, 334–342.

    Article  PubMed  CAS  Google Scholar 

  55. Moreland, L. W., Baumgartner, S. W., Schiff, M. H., et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147.

    Article  PubMed  CAS  Google Scholar 

  56. Moreland, L. W., Schiff, M. H., Baumgartner, S. W., et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478–486.

    PubMed  CAS  Google Scholar 

  57. Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Eng. J. Med. 340, 253–259.

    Article  CAS  Google Scholar 

  58. Bathon, J. M., Martin, R. W., Fleischmann, R. M., et al. (2000) A comparison of etanercept and methotrexate in patients with early Rheumatoid Arthritis. N. Engl. J. Med. 343, 1586–1593.

    Article  PubMed  CAS  Google Scholar 

  59. Abraham, E., Wunderink, R., Silverman, H., et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis sydrome. A randomized, controlled, double-blind, multicenter, clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273, 934–941.

    Article  PubMed  CAS  Google Scholar 

  60. Fischer, Jr. C. J., Opal, S. M., Dhainaut, J.-F., et al. (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. 21, 318–327.

    Article  Google Scholar 

  61. Reinhart, K., Wiegand-Lohnert, C., Grimminger, F., et al. (1996) Assessment of the safety and efficacy of the antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. 24, 733–742.

    Article  PubMed  CAS  Google Scholar 

  62. Fekade, D., Knox, K., Hussein, K., et al. (1996) Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N. Engl. J. Med. 335, 311–315.

    Article  PubMed  CAS  Google Scholar 

  63. Van Dullemen, H. M., Van Deventer, S. J. H., Hommes, D. W., et al. (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129–135.

    Article  PubMed  Google Scholar 

  64. McCabe, R. P., Woody, J. N., van Deventer, S., et al. (1996) A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology Suppl. 110, A962.

    Google Scholar 

  65. Targan, S. R., Hanauer, S. B., van Deventer, S. J., et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Disease. N. Engl. J. Med. 337, 1029–1035.

    Article  PubMed  CAS  Google Scholar 

  66. Stack, W. A., Mann, S. D., Roy, A. J., et al. (1997) Randomised controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn’s disease. Lancet 349, 521–524.

    Article  PubMed  CAS  Google Scholar 

  67. Charles, P., Elliott, M. J., Davis, D., et al. (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163, 1521–1528.

    PubMed  CAS  Google Scholar 

  68. Ulfgren, A.-K., Andersson, U., Engström, M., Klareskog, L., Maini, R. N., and Taylor, P. C. (2000) Systemic anti-TNFα therapy in rheumatoid arthritis down-regulates synovial TNFα synthesis. Arthritis Rheum. 43, 2391–2396.

    Article  PubMed  CAS  Google Scholar 

  69. Paleolog, E. M., Elliott, M. J., Woody, J. N., Feldmann, M., and Maini, R. N. (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum. 39, 1082–1091.

    Article  PubMed  CAS  Google Scholar 

  70. Tak, P. P., Taylor, P. C., Breedveld, F. C., et al. (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 39, 1077–1081.

    Article  PubMed  CAS  Google Scholar 

  71. Taylor, P. C., Maini, R. N., Tak, P. P., et al. (1997) Reply to Decrease in cell adhesion molecules by treatment with anti-tumor necrosis factor a monoclonal antibody. Arthritis Rheum. 4, 789,790.

    Article  Google Scholar 

  72. Taylor, P. C., Peters, A. M., Paleolog, E., et al. (2000) TNFα blockade in patients with rheumatoid arthritis reduces chemokines and leukocyte traffic to joints. Arthritis Rheum. 43, 38–47.

    Article  PubMed  CAS  Google Scholar 

  73. Gearing, A. J. H. and Newman, W. (1993) Circulating adhesion molecules in disease. Immunol. Today 14, 506–512.

    Article  PubMed  CAS  Google Scholar 

  74. Leeuwenberg, J. F. M., Smeets, E. F., Neefjes, J. J., et al. (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77, 543–549.

    PubMed  CAS  Google Scholar 

  75. Taylor, P. C., Peters, A. M., Glass, D. M., and Maini, R. N. (1999) Effect of treatment of Rheumatoid patients with anti-TNFα on reticuloendothelial and intrapulmonary granulocyte traffic. Clin. Sci. 97, 85–89.

    Article  PubMed  CAS  Google Scholar 

  76. Alvaro-Gracia, J.M., Zvaifler, N.J., Brown, C.B., Kaushansky, K., and Firestein, G. S. (1991) Cytokines in chronic inflammatory arthritis. J. Immunol. 146, 3365–3371.

    PubMed  CAS  Google Scholar 

  77. Haworth, C., Brennan, F. M., Chantry, D., Turner, M., Maini, R. N., and Feldmann, M. (1991) Expression of granulocytemacrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur. J. Immunol. 21, 2575–2579.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Kennedy Institute Division, Imperial College School of Medicine, 1 Aspenlea Road, W6 8LH, London

    Peter C. Taylor MA, PhD (FRCP, Senior Lecturer and Honorary Consultant Rheumatologist)

Authors
  1. Peter C. Taylor MA, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter C. Taylor MA, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, P.C. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol 19, 153–168 (2001). https://doi.org/10.1385/MB:19:2:153

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/MB:19:2:153

Index Entries

Search

Navigation